András Tálas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
András Tálas has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Ervin Welker
Institute of Molecular Life Sciences, HUN-REN Research Centre for Natural Sciences , Budapest H-1117
8 shared publications - Gerald Schwank
Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
7 shared publications - Péter István Kulcsár
Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
7 shared publications - Lukas Schmidheini
Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
5 shared publications - Nicolas Mathis
Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland
5 shared publications - Elfrieda Fodor
Institute of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences, Szeged, H-6726, Hungary
4 shared publications
Latest Publications
- 13 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (849) , eadz2557
Prime editing of a pathogenic Scn1a allele ameliorates seizure phenotypes in a GEFS + mouse model
Generalized epilepsy with febrile seizures plus (GEFS + ) is an inherited epileptic disorder predominantly linked to autosomal-dominant, loss-of-function mutations in the sodium voltage-gated channel α subunit 1 ( SCN1A ) gene, which encodes the α subunit of the neuronal voltage-gated sodium ion channel type 1 (Na V 1.1). Reduced Na V 1.1 function in γ-aminobutyric acid (GABA)–ergic interneurons impairs inhibitory signaling and leads to neuronal hyperexcitability. Clinically, GEFS + is characterized by a spectrum of seizure types, often beginning with febrile seizures in early childhood and progressing to generalized tonic-clonic seizures later in life. Here, we used prime editing to correct the pathogenic SCN1A -K1270T mutation in the Scn1a KT/ + mouse model of GEFS + . Adeno-associated viral (AAV) vectors were used to deliver an intein-split prime editor under the control of a neuron-specific promoter into the cerebral ventricles of neonatal mice. This enabled efficient in vivo editing, achieving 34.7 ± 14.5% correction of the mutant allele in cortical bulk DNA, 81.2 ± 5.9% correction of mRNA, and improved multiple disease-relevant phenotypes. Survival increased from 80% in control-treated animals to 100% in treated mice, cortical inhibitory neuron transmission was improved (frequencies of inhibitory postsynaptic currents were increased from 0.32 to 1.32 hertz), and the frequency of induced febrile seizures decreased from 78.6% to 13.3%, approaching the frequency seen in wild-type mice (8%). These findings suggest the therapeutic potential of prime editing for the treatment of patients with SCN1A -associated GEFS + .
- 13 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (849) , eadz2557
Prime editing of a pathogenic Scn1a allele ameliorates seizure phenotypes in a GEFS + mouse model
Generalized epilepsy with febrile seizures plus (GEFS + ) is an inherited epileptic disorder predominantly linked to autosomal-dominant, loss-of-function mutations in the sodium voltage-gated channel α subunit 1 ( SCN1A ) gene, which encodes the α subunit of the neuronal voltage-gated sodium ion channel type 1 (Na V 1.1). Reduced Na V 1.1 function in γ-aminobutyric acid (GABA)–ergic interneurons impairs inhibitory signaling and leads to neuronal hyperexcitability. Clinically, GEFS + is characterized by a spectrum of seizure types, often beginning with febrile seizures in early childhood and progressing to generalized tonic-clonic seizures later in life. Here, we used prime editing to correct the pathogenic SCN1A -K1270T mutation in the Scn1a KT/ + mouse model of GEFS + . Adeno-associated viral (AAV) vectors were used to deliver an intein-split prime editor under the control of a neuron-specific promoter into the cerebral ventricles of neonatal mice. This enabled efficient in vivo editing, achieving 34.7 ± 14.5% correction of the mutant allele in cortical bulk DNA, 81.2 ± 5.9% correction of mRNA, and improved multiple disease-relevant phenotypes. Survival increased from 80% in control-treated animals to 100% in treated mice, cortical inhibitory neuron transmission was improved (frequencies of inhibitory postsynaptic currents were increased from 0.32 to 1.32 hertz), and the frequency of induced febrile seizures decreased from 78.6% to 13.3%, approaching the frequency seen in wild-type mice (8%). These findings suggest the therapeutic potential of prime editing for the treatment of patients with SCN1A -associated GEFS + .
- 13 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (849) , eaec7274
RNA-LNP–mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type I
Citrullinemia type I (CTLN1) is a severe urea cycle disorder caused by pathogenic variants in the ASS1 (argininosuccinate synthetase 1) gene, for which liver transplantation remains the only curative option. Here, we used prime editing to correct the Ass1 fold mouse model of CTLN1. Adeno-associated virus (AAV)–mediated delivery of the PE7 prime editor with an optimized prime editing guide RNA (pegRNA) achieved 71 and 54% correction of the pathogenic Ass1 mutation in hepatocytes of neonates and juveniles, respectively. Delivery of mRNA-encoded PE7 and synthetic pegRNA via lipid nanoparticles (LNPs) resulted in 24% correction after a single 3 mg kg −1 dose in neonates and 13% after three 4 mg kg −1 doses in juveniles. All treated groups showed full normalization of survival and of blood citrulline and ammonia concentrations, with restored urea cycle function and correction of natural behavior defects. Consistent with these findings, immunostaining demonstrated restoration of wild-type–like ASS1 protein localization in functionally relevant periportal and intermediate-zone hepatocytes. Editing was confined to the liver, with minimal indel formation and off-target activity and only transient elevations in liver enzymes. In a cellular reporter system, 6 of 15 recurrent human pathogenic ASS1 mutations studied, including the most common ASS1 G390R variant, were corrected with similar or higher efficiencies than Ass1 fold . These findings highlight prime editing as a precise and potentially curative treatment strategy for individuals with CTLN1 and other genetic liver diseases.
- 13 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (849) , eaec7274
RNA-LNP–mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type I
Citrullinemia type I (CTLN1) is a severe urea cycle disorder caused by pathogenic variants in the ASS1 (argininosuccinate synthetase 1) gene, for which liver transplantation remains the only curative option. Here, we used prime editing to correct the Ass1 fold mouse model of CTLN1. Adeno-associated virus (AAV)–mediated delivery of the PE7 prime editor with an optimized prime editing guide RNA (pegRNA) achieved 71 and 54% correction of the pathogenic Ass1 mutation in hepatocytes of neonates and juveniles, respectively. Delivery of mRNA-encoded PE7 and synthetic pegRNA via lipid nanoparticles (LNPs) resulted in 24% correction after a single 3 mg kg −1 dose in neonates and 13% after three 4 mg kg −1 doses in juveniles. All treated groups showed full normalization of survival and of blood citrulline and ammonia concentrations, with restored urea cycle function and correction of natural behavior defects. Consistent with these findings, immunostaining demonstrated restoration of wild-type–like ASS1 protein localization in functionally relevant periportal and intermediate-zone hepatocytes. Editing was confined to the liver, with minimal indel formation and off-target activity and only transient elevations in liver enzymes. In a cellular reporter system, 6 of 15 recurrent human pathogenic ASS1 mutations studied, including the most common ASS1 G390R variant, were corrected with similar or higher efficiencies than Ass1 fold . These findings highlight prime editing as a precise and potentially curative treatment strategy for individuals with CTLN1 and other genetic liver diseases.
- Top Cited Papers
- 12 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6790) , eadz1884
Programmable genome editing in human cells using RNA-guided bridge recombinases
Site-specific insertion of gene-sized DNA fragments remains an unmet need in the field of genome editing. IS110-family serine recombinases have recently been shown to mediate programmable DNA recombination in bacteria by using a bispecific RNA guide (bridge RNA) that simultaneously recognizes target and donor sites. In this work, we have shown that the bridge recombinase ISCro4 is highly active in human cells and provided structural insights into its enhanced activity. Using plasmid- or all-RNA–based delivery, ISCro4 supports programmable multikilobase excisions and inversions and facilitates donor DNA insertion at genomic sites with efficiencies that exceed 6%. Last, we assessed ISCro4 specificity and off-target activity. These results establish a framework for the development of bridge recombinases as next-generation tools for editing modalities that are beyond the capabilities of current technologies.
- 12 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 391 (6790) , eadz1884
Top Cited PapersProgrammable genome editing in human cells using RNA-guided bridge recombinases
Site-specific insertion of gene-sized DNA fragments remains an unmet need in the field of genome editing. IS110-family serine recombinases have recently been shown to mediate programmable DNA recombination in bacteria by using a bispecific RNA guide (bridge RNA) that simultaneously recognizes target and donor sites. In this work, we have shown that the bridge recombinase ISCro4 is highly active in human cells and provided structural insights into its enhanced activity. Using plasmid- or all-RNA–based delivery, ISCro4 supports programmable multikilobase excisions and inversions and facilitates donor DNA insertion at genomic sites with efficiencies that exceed 6%. Last, we assessed ISCro4 specificity and off-target activity. These results establish a framework for the development of bridge recombinases as next-generation tools for editing modalities that are beyond the capabilities of current technologies.
- Top Cited PapersOpen Access
- 20 May 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (10) , 1-14
Treatment of a metabolic liver disease in mice with a transient prime editing approach
Prime editing is a versatile genome editing technology that circumvents the need for DNA double-strand break formation and homology-directed repair, making it particularly suitable for in vivo correction of pathogenic mutations. Here we developed liver-specific prime editing approaches with temporally restricted prime editor (PE) expression. We first established a dual-delivery approach where the prime editor guide RNA is continuously expressed from adeno-associated viral vectors and only the PE is transiently delivered as nucleoside-modified mRNA encapsulated in lipid nanoparticles (LNP). This strategy achieved 26.2% editing with PEmax and 47.4% editing with PE7 at the Dnmt1 locus using a single 2 mg kg−1 dose of mRNA–LNP. When targeting the pathogenic Pah enu2 mutation in a phenylketonuria mouse model, gene correction rates reached 4.3% with PEmax and 20.7% with PE7 after three doses of 2 mg kg−1 mRNA–LNP, effectively reducing blood l-phenylalanine levels from over 1,500 µmol l−1 to below the therapeutic threshold of 360 µmol l−1. Encouraged by the high efficiency of PE7, we next explored a simplified approach where PE7 mRNA was co-delivered with synthetic prime editor guide RNAs encapsulated in LNP. This strategy yielded 35.9% editing after two doses of RNA–LNP at the Dnmt1 locus and 8.0% editing after three doses of RNA–LNP at the Pah enu2 locus, again reducing l-phenylalanine levels below 360 µmol l−1. These findings highlight the therapeutic potential of mRNA–LNP-based prime editing for treating phenylketonuria and other genetic liver diseases, offering a scalable and efficient platform for future clinical translation.
- 20 May 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (10) , 1-14
Top Cited PapersOpen AccessTreatment of a metabolic liver disease in mice with a transient prime editing approach
Prime editing is a versatile genome editing technology that circumvents the need for DNA double-strand break formation and homology-directed repair, making it particularly suitable for in vivo correction of pathogenic mutations. Here we developed liver-specific prime editing approaches with temporally restricted prime editor (PE) expression. We first established a dual-delivery approach where the prime editor guide RNA is continuously expressed from adeno-associated viral vectors and only the PE is transiently delivered as nucleoside-modified mRNA encapsulated in lipid nanoparticles (LNP). This strategy achieved 26.2% editing with PEmax and 47.4% editing with PE7 at the Dnmt1 locus using a single 2 mg kg−1 dose of mRNA–LNP. When targeting the pathogenic Pah enu2 mutation in a phenylketonuria mouse model, gene correction rates reached 4.3% with PEmax and 20.7% with PE7 after three doses of 2 mg kg−1 mRNA–LNP, effectively reducing blood l-phenylalanine levels from over 1,500 µmol l−1 to below the therapeutic threshold of 360 µmol l−1. Encouraged by the high efficiency of PE7, we next explored a simplified approach where PE7 mRNA was co-delivered with synthetic prime editor guide RNAs encapsulated in LNP. This strategy yielded 35.9% editing after two doses of RNA–LNP at the Dnmt1 locus and 8.0% editing after three doses of RNA–LNP at the Pah enu2 locus, again reducing l-phenylalanine levels below 360 µmol l−1. These findings highlight the therapeutic potential of mRNA–LNP-based prime editing for treating phenylketonuria and other genetic liver diseases, offering a scalable and efficient platform for future clinical translation.
- 12 August 2024
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (5) , 822
Publisher Correction: Machine learning prediction of prime editing efficiency across diverse chromatin contexts
- 12 August 2024
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (5) , 822
Publisher Correction: Machine learning prediction of prime editing efficiency across diverse chromatin contexts
- Top Cited Papers
- 21 June 2024
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (5) , 712-719
Machine learning prediction of prime editing efficiency across diverse chromatin contexts
The success of prime editing depends on the prime editing guide RNA (pegRNA) design and target locus. Here, we developed machine learning models that reliably predict prime editing efficiency. PRIDICT2.0 assesses the performance of pegRNAs for all edit types up to 15 bp in length in mismatch repair-deficient and mismatch repair-proficient cell lines and in vivo in primary cells. With ePRIDICT, we further developed a model that quantifies how local chromatin environments impact prime editing rates.
- 21 June 2024
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (5) , 712-719
Top Cited PapersMachine learning prediction of prime editing efficiency across diverse chromatin contexts
The success of prime editing depends on the prime editing guide RNA (pegRNA) design and target locus. Here, we developed machine learning models that reliably predict prime editing efficiency. PRIDICT2.0 assesses the performance of pegRNAs for all edit types up to 15 bp in length in mismatch repair-deficient and mismatch repair-proficient cell lines and in vivo in primary cells. With ePRIDICT, we further developed a model that quantifies how local chromatin environments impact prime editing rates.
- Open Access
Predicting prime editing efficiency across diverse edit types and chromatin contexts with machine learning
Prime editing is a powerful genome editing technology, but its efficiency varies depending on the pegRNA design and target locus. Existing computational models for predicting prime editing rates are limited by their focus on specific edit types and by omitting the local chromatin environment. In our study, we developed machine learning models that predict prime editing efficiencies across a wide range of edit types up to 15 bp (’PRIDICT2.0’) and in different chromatin contexts (’ePRIDICT’). Both models can be accessed at www.pridict.it .
Open AccessPredicting prime editing efficiency across diverse edit types and chromatin contexts with machine learning
Prime editing is a powerful genome editing technology, but its efficiency varies depending on the pegRNA design and target locus. Existing computational models for predicting prime editing rates are limited by their focus on specific edit types and by omitting the local chromatin environment. In our study, we developed machine learning models that predict prime editing efficiencies across a wide range of edit types up to 15 bp (’PRIDICT2.0’) and in different chromatin contexts (’ePRIDICT’). Both models can be accessed at www.pridict.it .
- Open Access
Target-matched increased fidelity SpCas9 variants can edit any target without genome-wide off-target effects
Streptococcus pyogenes Cas9 (SpCas9) has been employed as a genome engineering tool with a promising potential within therapeutics. However, its off- target effects pose a major limitation for applications requiring high specificity. Approaches developed to date to mitigate this effect, including any of the increased fidelity (i.e., high-fidelity) SpCas9 variants, only provide efficient editing on a relatively small fraction of targets without detectable off-targets. Upon addressing this problem, we have revealed a rather unexpected cleavability ranking of target sequences, and a cleavage rule that governs the on-target and off-target cleavage of increased fidelity SpCas9 variants but not that of SpCas9-NG or xCas9. As a consequence of this rule, each target needs a matching-fidelity, optimal variant for efficient cleavage without detectable off-target effects. By exploiting this finding, we have developed an extended set of increased fidelity variants spanning across a wide range, with differences in fidelity small enough to comprise an optimal variant for any target, irrespective of its cleavability ranking. We have demonstrated efficient editing with maximum specificity even on those targets that have been challenged but failed in previous studies.
Open AccessTarget-matched increased fidelity SpCas9 variants can edit any target without genome-wide off-target effects
Streptococcus pyogenes Cas9 (SpCas9) has been employed as a genome engineering tool with a promising potential within therapeutics. However, its off- target effects pose a major limitation for applications requiring high specificity. Approaches developed to date to mitigate this effect, including any of the increased fidelity (i.e., high-fidelity) SpCas9 variants, only provide efficient editing on a relatively small fraction of targets without detectable off-targets. Upon addressing this problem, we have revealed a rather unexpected cleavability ranking of target sequences, and a cleavage rule that governs the on-target and off-target cleavage of increased fidelity SpCas9 variants but not that of SpCas9-NG or xCas9. As a consequence of this rule, each target needs a matching-fidelity, optimal variant for efficient cleavage without detectable off-target effects. By exploiting this finding, we have developed an extended set of increased fidelity variants spanning across a wide range, with differences in fidelity small enough to comprise an optimal variant for any target, irrespective of its cleavability ranking. We have demonstrated efficient editing with maximum specificity even on those targets that have been challenged but failed in previous studies.
- Open Access
- 23 February 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
PEAR, a flexible fluorescent reporter for the identification and enrichment of successfully prime edited cells
Prime editing is a recently developed CRISPR/Cas9 based gene engineering tool that allows the introduction of short insertions, deletions, and substitutions into the genome. However, the efficiency of prime editing, which typically achieves editing rates of around 10%–30%, has not matched its versatility. Here, we introduce the prime editor activity reporter (PEAR), a sensitive fluorescent tool for identifying single cells with prime editing activity. PEAR has no background fluorescence and specifically indicates prime editing events. Its design provides apparently unlimited flexibility for sequence variation along the entire length of the spacer sequence, making it uniquely suited for systematic investigation of sequence features that influence prime editing activity. The use of PEAR as an enrichment marker for prime editing can increase the edited population by up to 84%, thus significantly improving the applicability of prime editing for basic research and biotechnological applications.
- 23 February 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Open AccessPEAR, a flexible fluorescent reporter for the identification and enrichment of successfully prime edited cells
Prime editing is a recently developed CRISPR/Cas9 based gene engineering tool that allows the introduction of short insertions, deletions, and substitutions into the genome. However, the efficiency of prime editing, which typically achieves editing rates of around 10%–30%, has not matched its versatility. Here, we introduce the prime editor activity reporter (PEAR), a sensitive fluorescent tool for identifying single cells with prime editing activity. PEAR has no background fluorescence and specifically indicates prime editing events. Its design provides apparently unlimited flexibility for sequence variation along the entire length of the spacer sequence, making it uniquely suited for systematic investigation of sequence features that influence prime editing activity. The use of PEAR as an enrichment marker for prime editing can increase the edited population by up to 84%, thus significantly improving the applicability of prime editing for basic research and biotechnological applications.
- Open Access
- 3 November 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-14
BEAR reveals that increased fidelity variants can successfully reduce the mismatch tolerance of adenine but not cytosine base editors
Adenine and cytosine base editors (ABE, CBE) allow for precision genome engineering. Here, Base Editor Activity Reporter (BEAR), a plasmid-based fluorescent tool is introduced, which can be applied to report on ABE and CBE editing in a virtually unrestricted sequence context or to label base edited cells for enrichment. Using BEAR-enrichment, we increase the yield of base editing performed by nuclease inactive base editors to the level of the nickase versions while maintaining significantly lower indel background. Furthermore, by exploiting the semi-high-throughput potential of BEAR, we examine whether increased fidelity SpCas9 variants can be used to decrease SpCas9-dependent off-target effects of ABE and CBE. Comparing them on the same target sets reveals that CBE remains active on sequences, where increased fidelity mutations and/or mismatches decrease the activity of ABE. Our results suggest that the deaminase domain of ABE is less effective to act on rather transiently separated target DNA strands, than that of CBE explaining its lower mismatch tolerance.
- 3 November 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-14
Open AccessBEAR reveals that increased fidelity variants can successfully reduce the mismatch tolerance of adenine but not cytosine base editors
Adenine and cytosine base editors (ABE, CBE) allow for precision genome engineering. Here, Base Editor Activity Reporter (BEAR), a plasmid-based fluorescent tool is introduced, which can be applied to report on ABE and CBE editing in a virtually unrestricted sequence context or to label base edited cells for enrichment. Using BEAR-enrichment, we increase the yield of base editing performed by nuclease inactive base editors to the level of the nickase versions while maintaining significantly lower indel background. Furthermore, by exploiting the semi-high-throughput potential of BEAR, we examine whether increased fidelity SpCas9 variants can be used to decrease SpCas9-dependent off-target effects of ABE and CBE. Comparing them on the same target sets reveals that CBE remains active on sequences, where increased fidelity mutations and/or mismatches decrease the activity of ABE. Our results suggest that the deaminase domain of ABE is less effective to act on rather transiently separated target DNA strands, than that of CBE explaining its lower mismatch tolerance.